619 filings
Page 4 of 31
D
ENTO
Entero Therapeutics Inc.
21 Sep 23
$1.47 mm in options, sold $1.47 mm, 1 investor
4:12pm
4
Casamento Charles J
18 Sep 23
First Wave BioPharma / CHARLES J CASAMENTO ownership change
5:44pm
8-K
ENTO
Entero Therapeutics Inc.
15 Sep 23
Entry into a Material Definitive Agreement
4:05pm
144
Casamento Charles J
15 Sep 23
Notice of proposed sale of securities
3:03pm
8-K
ENTO
Entero Therapeutics Inc.
14 Sep 23
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
6:19am
144
ENTO
Entero Therapeutics Inc.
7 Sep 23
Notice of proposed sale of securities
4:08pm
4
Casamento Charles J
5 Sep 23
First Wave BioPharma / CHARLES J CASAMENTO ownership change
8:08pm
8-K
ENTO
Entero Therapeutics Inc.
25 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
S-8
ENTO
Entero Therapeutics Inc.
21 Aug 23
Registration of securities for employees
4:06pm
8-K
ENTO
Entero Therapeutics Inc.
18 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
10-Q
2023 Q2
ENTO
Entero Therapeutics Inc.
Quarterly report
14 Aug 23
4:16pm
8-K
ENTO
Entero Therapeutics Inc.
21 Jul 23
First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering
8:19am
424B4
ENTO
Entero Therapeutics Inc.
20 Jul 23
Prospectus supplement with pricing info
5:26pm
EFFECT
ENTO
Entero Therapeutics Inc.
18 Jul 23
Notice of effectiveness
12:15am
CORRESP
ENTO
Entero Therapeutics Inc.
14 Jul 23
Correspondence with SEC
12:00am
CORRESP
ENTO
Entero Therapeutics Inc.
14 Jul 23
Correspondence with SEC
12:00am
CORRESP
ENTO
Entero Therapeutics Inc.
14 Jul 23
Correspondence with SEC
12:00am
CORRESP
ENTO
Entero Therapeutics Inc.
14 Jul 23
Correspondence with SEC
12:00am
S-1/A
ENTO
Entero Therapeutics Inc.
IPO registration (amended)
13 Jul 23
7:38am
8-K
ENTO
Entero Therapeutics Inc.
13 Jul 23
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
12:00am